STSA News and Press, Satsuma Pharmaceuticals Inc. From 02/06/20

AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Thinly traded micro cap Satsuma Pharmaceuticals ( STSA +10.7% ) is up on below-average volume, a modest 64K shares, adding to yesterday's  30%  pop, also on light volume. More news on: Satsuma Pharmaceuticals, Inc., Bausch Health Companies Inc., Healthcare stocks news, Stocks o...

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safety with its lead product candidate, STS1...

Gainers:  LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...